| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.fabinolife.com | |
| Market Cap | 6.11 Cr. | |
| Enterprise Value(EV) | 6.60 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.05 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | 566.03 | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 42.15 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 19.59 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 1.49 | Calculated using Price: 29.11 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.21 Cr. | 2,100,000 Shares |
| FaceValue | 10 | |
| About Fabino Life Sciences Ltd. | ||
| The company is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness focused consumer products. The company's core business is marketing of pharmaceutical formulation & products in domestic market through own distribution network and sales force under own brand name, getting its ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc. | ||
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
-26.43% |
| 3 Month |
|
-1.32% |
| 6 Month |
|
+4.71% |
| 1 Year |
|
-9.03% |
| 2 Year |
|
+10.90% |
| 5 Year |
|
|
| 10 Year |
|
| 5 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 0.02 | 10.8 | 3.05 | 1.74 | 0.26 | |
| Return on Capital Employed (%) | 9.44 | 12.36 | 2.92 | 2.48 | 0.58 | |
| Return on Assets (%) | 0 | 1.14 | 1.04 | 1.37 | 0.22 |
| Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 1 | 1 | 1 | 4 | 4 | 4 | |
| Non Curr. Liab. | 0 | 1 | 0 | 0 | 0 | 1 | |
| Curr. Liab. | 8 | 2 | 1 | 0 | 0 | 1 | |
| Minority Int. | |||||||
| Equity & Liab. | 9 | 4 | 2 | 5 | 5 | 5 | |
| Non Curr. Assets | 1 | 1 | 0 | 0 | 0 | 0 | |
| Curr. Assets | 8 | 3 | 2 | 4 | 5 | 5 | |
| Misc. Exp. not W/O | |||||||
| Total Assets | 9 | 4 | 2 | 5 | 5 | 5 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Net Sales | 3 | 8 | 3 | 4 | 3 | |
| Other Income | 0 | 0 | ||||
| Total Income | 3 | 8 | 3 | 4 | 3 | |
| Total Expenditure | -2 | -7 | -3 | -4 | -3 | |
| PBIDT | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | |||
| Exceptional Items | ||||||
| PAT | 0 | 0 | 0 | 0 | ||
| Adjusted EPS | 5 | 0 | 0 | 0 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 2 | 0 | -2 | -1 | |
| Cash Fr. Inv. | 0 | 0 | 0 | 0 | ||
| Cash Fr. Finan. | 0 | -2 | 0 | 2 | 0 | |
| Net Change | 0 | 0 | 1 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 1 | 0 |
|
Tue, 30 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: KANCHI GEHLOT Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: info@fabinolife.com Name of the Chief Financial Officer: PANKAJ JAIN Designation: CHEIF FINANCIAL OFFICER EmailId: FABINOIPO2021@GMAIL.COM Date: 30/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Tue, 16 Apr 2024
Certificate As Per Regulation 40 (9) For The Year Ended March 31 2024 Compliance certificate as per Regulation 40(9) For the Year Ended March 31 2024. |
|||||||||||||||||||||
|
Mon, 15 Apr 2024
Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Period Ended March 31 2024. Compliance certificate Under Regulation 7(3) of SEBI (Listing obligation and Disclosure requirements) Regulations 2015 for the period ended March 31 2024 |
|
No Scans Found |
